Immune checkpoint therapy for non-small-cell lung cancer: an update (Q38727542)

5 September 2017

1 reference

title

Immune checkpoint therapy for non-small-cell lung cancer: an update (English)

1 reference

5 September 2017

1 reference

2

Roy S Herbst

1 reference

5 September 2017

Bing Xia

1

1 reference

5 September 2017

9 February 2016

1 reference

5 September 2017

1 reference

5 September 2017

8

1 reference

5 September 2017

3

1 reference

5 September 2017

279-298

1 reference

5 September 2017

Cancer statistics, 2014

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.123

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.123

B7-H1/PD-1 blockade therapy in non-small cell lung cancer: current status and future direction

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.123

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.123

Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.123

EGFR T790M resistance mutation in non small-cell lung carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.123

Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.123

Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.123

The anaplastic lymphoma kinase in the pathogenesis of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.123

EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.123

The blockade of immune checkpoints in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.123

Immune checkpoint blockade: a common denominator approach to cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.123

Cancer immunotherapy: a future paradigm shift in the treatment of non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.123

Checkpoint blockade in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.123

Inducible expression of B7-H1 (PD-L1) and its selective role in tumor site immune modulation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.123

Enhancement of antitumor immunity by CTLA-4 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.123

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.123

CD28 and CTLA-4 coreceptor expression and signal transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.123

Cd28 and Ctla-4, two related members of the Ig supergene family, are tightly linked on proximal mouse chromosome 1

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.123

CD80 (B7-1) binds both CD28 and CTLA-4 with a low affinity and very fast kinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.123

New perspectives of CD28-B7-mediated T cell costimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.123

Distinct roles for CD28 and cytotoxic T lymphocyte-associated molecule-4 receptors during T cell activation?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.123

Mechanism responsible for T-cell antigen receptor- and CD28- or interleukin 1 (IL-1) receptor-initiated regulation of IL-2 gene expression by NF-kappaB

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.123

Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.123

Unifying concepts in CD28, ICOS and CTLA4 co-receptor signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.123

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.123

Molecular pathways: coexpression of immune checkpoint molecules: signaling pathways and implications for cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.123

The CD28 and CTLA-4 receptors associate with the serine/threonine phosphatase PP2A.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.123

CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.123

Ipilimumab: its potential in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.123

Regulatory T cells control antigen-specific expansion of Tfh cell number and humoral immune responses via the coreceptor CTLA-4.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.123

CTLA-4 control over Foxp3+ regulatory T cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.123

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.123

Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.123

Clinical development of the anti-CTLA-4 antibody tremelimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.123

Immunotherapy for lung cancer: for whom the bell tolls?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.123

The programmed death-1 ligand 1:B7-1 pathway restrains diabetogenic effector T cells in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.123

Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.123

Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.123

SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.123

PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3zeta signalosome and downstream signaling to PKCtheta

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.123

PD-1 signaling in primary T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.123

Blockade of programmed death-1 engagement accelerates graft-versus-host disease lethality by an IFN-gamma-dependent mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.123

Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.123

Nivolumab for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.123

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.123

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.123

Pembrolizumab for the treatment of non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.123

Immune checkpoint inhibitors in NSCLC.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.123

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.123

PD-L1 and PD-L2 modulate airway inflammation and iNKT-cell-dependent airway hyperreactivity in opposing directions

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.123

Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.123

Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.123

The new lung cancer staging system

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.123

Programmed death ligand-1 expression in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.123

Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.123

OX40- and CD27-mediated costimulation synergizes with anti-PD-L1 blockade by forcing exhausted CD8+ T cells to exit quiescence

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.123

Tumor-infiltrating regulatory T cells inhibit endogenous cytotoxic T cell responses to lung adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.123

Tremelimumab (CP-675,206), a cytotoxic T lymphocyte associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.123

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.123

Anti-programmed cell death protein-1/ligand-1 therapy in different cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.123

Nivolumab in NSCLC: latest evidence and clinical potential

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.123

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.123

The European Medicines Agency review of ipilimumab (Yervoy) for the treatment of advanced (unresectable or metastatic) melanoma in adults who have received prior therapy: summary of the scientific assessment of the Committee for Medicinal Products f

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.123

Targeting the immune system in non-small-cell lung cancer: bridging the gap between promising concept and therapeutic reality

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.123

Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.123

21 January 2018

Identifiers

DOI

10.2217/IMT.15.123

1 reference

5 September 2017

1 reference

PubMed ID

26860624